Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
14.03
+0.14 (1.04%)
Aug 12, 2026, 11:44 AM EDT - Market open
Kazia Therapeutics Revenue
In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 41.77K AUD, down -98.19%.
Revenue (ttm)
41.77K AUD
Revenue Growth
-98.19%
P/S Ratio
125.24
Revenue / Employee
6,961 AUD
Employees
6
Market Cap
160.26M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 41.77K | -2.27M | -98.19% |
| Jun 30, 2024 | 2.31M | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 15.18M | - | - |
| Jun 30, 2020 | - | - | - |
| Jun 30, 2019 | - | - | - |
| Jun 30, 2018 | 119.00K | -130.00K | -52.21% |
| Jun 30, 2017 | 249.00K | -157.00K | -38.67% |
| Jun 30, 2016 | 406.00K | 317.00K | 356.18% |
| Jun 30, 2015 | 89.00K | 2.00K | 2.30% |
| Jun 30, 2014 | 87.00K | -1.03M | -92.18% |
| Jun 30, 2013 | 1.11M | -335.00K | -23.15% |
| Jun 30, 2012 | 1.45M | -578.00K | -28.54% |
| Jun 30, 2011 | 2.03M | 241.00K | 13.51% |
| Jun 30, 2010 | 1.78M | -720.00K | -28.75% |
| Jun 30, 2009 | 2.50M | -10.78M | -81.15% |
| Jun 30, 2008 | 13.28M | -4.01M | -23.20% |
| Jun 30, 2007 | 17.30M | -150.00K | -0.86% |
| Jun 30, 2006 | 17.45M | 56.00K | 0.32% |
| Jun 30, 2005 | 17.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| LENZ Therapeutics | 21.48M |
| Caribou Biosciences | 11.20M |
| Armata Pharmaceuticals | 5.20M |
| Molecular Partners AG | 856.30K |
KZIA News
- 15 days ago - Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer - GlobeNewsWire
- 6 weeks ago - Kazia Therapeutics initiated with a Buy at BTIG - TheFly
- 2 months ago - Kazia Therapeutics initiated with a Buy at Lake Street - TheFly
- 2 months ago - Kazia Therapeutics appoints James Levine as CFO - TheFly
- 2 months ago - Kazia Therapeutics Appoints James Levine as Chief Financial Officer - PRNewsWire
- 2 months ago - Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer - PRNewsWire
- 4 months ago - Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer - TheFly
- 4 months ago - Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - PRNewsWire